(NASDAQ: VTGN) Vistagen Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.05%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.95%.
Vistagen Therapeutics's earnings in 2026 is -$58,943,000.On average, 4 Wall Street analysts forecast VTGN's earnings for 2027 to be -$69,486,911, with the lowest VTGN earnings forecast at -$67,893,492, and the highest VTGN earnings forecast at -$70,318,260. On average, 3 Wall Street analysts forecast VTGN's earnings for 2028 to be -$72,549,046, with the lowest VTGN earnings forecast at -$69,703,985, and the highest VTGN earnings forecast at -$74,682,841.
In 2029, VTGN is forecast to generate -$78,202,218 in earnings, with the lowest earnings forecast at -$75,135,465 and the highest earnings forecast at -$80,502,283.